v3.26.1
SCHEDULE I-ADDITIONAL FINANCIAL INFORMATION OF PARENT COMPANY
12 Months Ended
Dec. 31, 2025
SCHEDULE I-ADDITIONAL FINANCIAL INFORMATION OF PARENT COMPANY  
SCHEDULE I-ADDITIONAL FINANCIAL INFORMATION OF PARENT COMPANY

SCHEDULE I—ADDITIONAL FINANCIAL INFORMATION OF PARENT COMPANY

COOTEK (CAYMAN) INC.

CONDENSED BALANCE SHEETS

As of December 31, 

  ​ ​ ​

2024

  ​ ​ ​

2025

US$

US$

ASSETS

  ​

  ​

Current assets:

 

  ​

 

  ​

Cash and cash equivalents

 

245,740

1,006

Prepaid expenses and other current assets

 

1,670

Total current assets

 

247,410

1,006

Advances to subsidiaries and VIEs

 

21,908

121,376

TOTAL ASSETS

 

269,318

122,382

LIABILITIES AND SHAREHOLDERS’ DEFICIT

 

  ​

 

  ​

Current liabilities:

 

  ​

 

  ​

Accrued expenses and other current liabilities

136,353

100,571

Accrued salary and benefits

250,000

170,000

Other current liabilities

 

Total current liabilities

 

386,353

270,571

Advances from subsidiaries and VIEs

Other non-current liabilities

TOTAL LIABILITIES

 

386,353

270,571

SHAREHOLDERS’ DEFICIT:

 

  ​

 

  ​

Ordinary shares

 

48,372

48,372

Additional paid-in capital

 

218,379,858

218,417,583

Accumulated deficit

 

(216,859,796)

(216,937,975)

Accumulated other comprehensive loss

 

(1,685,469)

(1,676,169)

Total shareholders’ deficit

 

(117,035)

(148,189)

TOTAL LIABILITIES AND SHAREHOLDERS’ (DEFICIT)/ EQUITY

 

269,318

122,382

SCHEDULE I—ADDITIONAL FINANCIAL INFORMATION OF PARENT COMPANY

COOTEK (CAYMAN) INC.

CONDENSED STATEMENTS OF OPERATIONS

For the years ended December 31, 

  ​ ​ ​

2023

  ​ ​ ​

2024

  ​ ​ ​

2025

US$

US$

US$

Net revenues

Cost of revenues

 

Gross loss

 

Operating expenses:

 

General and administrative expenses

 

(1,468,711)

(438,071)

(374,879)

Research and development expenses

 

(39,909)

(60,297)

(24,033)

Sales and marketing expenses

 

Other operating income, net

136,129

136,129

40,585

Total operating expenses

 

(1,372,491)

(362,239)

(358,327)

Loss from operations

 

(1,372,491)

(362,239)

(358,327)

Interest expenses, net

(7,490)

1,652

4,740

Fair value change of derivatives

Foreign exchange gains (losses), net

 

(1)

(3)

Loss before income taxes and equity in earnings of subsidiaries

 

(1,379,982)

(360,590)

(353,587)

Net loss before equity in earnings of subsidiaries

 

(1,379,982)

(360,590)

(353,587)

Equity in (loss) income of subsidiaries and share of (loss) income from VIEs

 

(1,215,959)

424,159

275,408

Net (loss) income attributed to CooTek (Cayman) Inc.

 

(2,595,941)

63,569

(78,179)

SCHEDULE I—ADDITIONAL FINANCIAL INFORMATION OF PARENT COMPANY

COOTEK (CAYMAN) INC.

CONDENSED STATEMENTS OF CASH FLOWS

For the years ended December 31, 

  ​ ​ ​

2023

  ​ ​ ​

2024

  ​ ​ ​

2025

US$

US$

 

US$

Operating activities:

  ​

  ​

  ​

Net (loss) income

 

(2,595,941)

63,569

(78,179)

Equity in (income) loss of subsidiaries, VIEs and VIEs’ subsidiaries

 

1,215,959

(424,159)

(275,408)

Adjustment to reconcile net loss to net cash provided by (used in) operating activities:

 

Share-based compensation

 

704,565

134,560

37,725

Amortization of issuance cost and debt discounts related to convertible notes

51,797

Change in fair value of derivatives

Changes in assets and liabilities:

 

Accrued expenses and other current liabilities

 

292,842

(741,434)

(35,784)

Other receivables, deposits and other assets

1,692

1,670

Accrued salary and benefits

(138,975)

(33,000)

(80,000)

Other non-current liabilities

(136,129)

(35,783)

Net cash used in operating activities

 

(605,882)

(1,034,555)

(429,976)

Investing activities:

 

Advances to subsidiaries and VIEs

 

(4,819,580)

(974,894)

(2,136,760)

Repayment of advances to subsidiary

6,607,179

2,250,000

2,322,002

Net cash provided by investing activities

 

1,787,599

1,275,106

185,242

Financing activities:

 

Proceeds from issuance of ordinary shares upon exercise of options

Repayment of convertible notes

(1,806,453)

Net cash (used in) provided by financing activities

 

(1,806,453)

Net (decrease) increase in cash, cash equivalents and restricted cash

 

(624,736)

240,551

(244,734)

Cash, cash equivalents and restricted cash at beginning of year

 

629,925

5,189

245,740

Cash, cash equivalents and restricted cash at end of year

 

5,189

245,740

1,006

SCHEDULE I—COOTEK (CAYMAN) INC CONDENSED FINANCIAL STATEMENTS

Notes to Schedule I

1. Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year.

2. The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries and VIEs and VIEs’ subsidiaries. For the parent company, the Company records its investments in subsidiaries VIEs and VIEs subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments—Equity Method and Joint Ventures.

3. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The footnote disclosures provide certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the accompanying consolidated financial statements.

4. As of December 31, 2024 and 2025, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the Company.